Transparency Notification Received from Tolefi SA (Article 14 §1 of the Law of 2 May 2007)

Rhea-AI Summary

Celyad Oncology (Euronext & Nasdaq: CYAD) announced on May 3, 2021, that Tolefi SA holds 2,295,701 shares with a double voting right, exceeding the 25% ownership threshold. This notification highlights Tolefi's increased influence in corporate decisions. Celyad Oncology is focused on developing CAR T cell therapies for cancer, including a pipeline of allogeneic and autologous candidates. The company has received funding from the Walloon Region in Belgium to advance its research initiatives.

Positive

• Tolefi SA's shareholding surpasses 25%, potentially stabilizing investor confidence.
• Company continues to develop CAR T therapies for hematological and solid tumors.
• Financial support from the Walloon Region boosts research and development efforts.

Negative

• None.

MONT-SAINT-GUIBERT, Belgium, May 05, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that it has received a transparency notification from Tolefi SA, dated 3 May 2021.

Tolefi SA has notified that its 2.295.701 shares benefit from a double voting right as of May 3, 2021 and that its shareholding has crossed above the threshold of 25%. The full transparency notice is available on the Celyad website under the heading “Regulated Information”.

About Celyad Oncology SA

Celyad Oncology SA is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs. For more information, please visit www.celyad.com.

Forward-looking statements

This release may contain forward-looking statements, within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include statements regarding: the safety and clinical activity of Celyad Oncology’s pipelines and financial condition, results of operation and business outlook. Forward-looking statements may involve known and unknown risks and uncertainties which might cause actual results, financial condition, performance or achievements of Celyad Oncology to differ materially from those expressed or implied by such forward-looking statements. Such risk and uncertainty includes the expected date of the Phase 1 trial results in the first half of 2021, our development of additional shRNA-based allogenic candidates from our CYAD-200 series towards clinical trial, our financial and operating results and the duration and severity of the COVID-19 pandemic and government measures implemented in response thereto. A further list and description of these risks, uncertainties and other risks can be found in Celyad Oncology’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in its Annual Report on Form 20-F filed with the SEC on March 24, 2021 and subsequent filings and reports by Celyad Oncology. These forward-looking statements speak only as of the date of publication of this document and Celyad Oncology’s actual results may differ materially from those expressed or implied by these forward-looking statements. Celyad Oncology expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.

Investor and Media Contacts:

Sara Zelkovic
Communications & Investor Relations Director
Celyad Oncology
investors@celyad.com

Daniel Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com

Source: Celyad Oncology SA

FAQ

What recent notification did Celyad Oncology receive?

Celyad Oncology received a notification from Tolefi SA indicating that it holds 2,295,701 shares with a double voting right, surpassing the 25% ownership threshold.

What is the significance of Tolefi SA's shareholding in Celyad Oncology?

Tolefi SA's ownership of over 25% grants it increased influence in corporate decision-making, which can impact shareholder interests.

What therapies is Celyad Oncology developing?

Celyad Oncology is developing chimeric antigen receptor T cell (CAR T) therapies for both hematological malignancies and solid tumors.

What funding has Celyad Oncology received?

The company has received funding from the Walloon Region in Belgium to support the advancement of its CAR T cell therapy programs.

What is the stock symbol for Celyad Oncology?

The stock symbol for Celyad Oncology is CYAD, listed on both Euronext and Nasdaq.